Clinical Trial Update: Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) [Phase 3]

View source ↗

Summary

The document reports the completion of a Phase 3 trial evaluating re-injection of NX-1207 for benign prostatic hyperplasia (BPH). The study status is listed as …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Prostatic Hyperplasia

Drugs mentioned

• NX-1207

Snippet

Sponsor: Nymox Corporation | Conditions: Benign Prostatic Hyperplasia | Phase 3 | Status: COMPLETED